A basic review on systemic treatment options in WHO grade II-III gliomas

Mair, Maximilian J.; Geurts, Marjolein; Bent, Martin J. van den; Berghoff, Anna S.

doi:10.1016/j.ctrv.2020.102124

Cited by 54 publications

(57 citation statements)

References 58 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Malignant gliomas are heterogeneous, highly invasive primary brain tumors and are managed by surgical removal of as much of the tumor bulk as is considered safe, followed by fractionated radiotherapy (RT; typically 60 Gy in 30–35 fractions), and concurrent chemotherapy, which is given continuously for at least an additional six months after cessation of RT [7] . Asymptomatic benign brain tumors can be followed up frequently until they become symptomatic, and then surgically resected and treated with adjuvant radiotherapy (RT) [8] .…”

Section: Introductionmentioning

confidence: 99%

Health-related quality of life in patients with primary brain tumors during and three months after treatment with proton beam therapy

Langegård

Fransson

Björk‐Eriksson

et al. 2021

Technical Innovations & Patient Support in Radiation Oncolo

View full text Add to dashboard Cite

Background: Proton beam therapy (PBT) is increasingly administered to patients with primary brain tumors. Benefits of new treatments must be weighed against side effects and possible deterioration in health-related quality of life (HRQoL). The aim of this study was to describe and compare HRQoL, including acute symptom experiences and associated factors, in patients with malignant and benign brain tumors treated with PBT. Materials and Methods: Adult PBT-treated patients with primary brain tumors (n = 266) were studied. HRQoL was assessed with EORTC QLQ-C30, QLQ-BN20, HADS, ISI and MFI before, during and three months after treatment. Associations with demographic and medical factors were explored. Results: Between baseline and three months post-treatment: HRQoL decreased significantly in the global health/QOL domains physical functioning, role functioning and cognitive functioning in the malignant group, global health/QOL and physical functioning decreased significantly in the benign group, more comorbidity was significantly associated with increased motor dysfunction, leg weakness, headache and future uncertainty. Fatigue and depression were the most frequent symptoms in both groups. Independent predictors of risk factor recognition were age, sex, chemotherapy, comorbidity and education level. Discussion: Global health/QOL in patient with brain tumors is very complex and multidimensional. Symptoms are interrelated and related to patient, tumor and treatment factors. It is important to identify aspects of HRQoL that may be affected by treatment. These include both benefits, expected to improve HRQoL, and negative changes such as symptom experience and influencing factors. Evidence-based guidelines are needed for symptom management, and for high quality of care for patients experiencing low PBT-related HRQoL.

show abstract

Section: Introductionmentioning

confidence: 99%

Health-related quality of life in patients with primary brain tumors during and three months after treatment with proton beam therapy

Langegård

Fransson

Björk‐Eriksson

et al. 2021

Technical Innovations & Patient Support in Radiation Oncolo

View full text Add to dashboard Cite

show abstract

“…The concept of lower-grade glioma (LGG, WHO Grades II and III) was proposed after the update to classify the central nervous system tumors by WHO in 2016 [3]. Compared to glioblastoma, LGGs were known to have a better prognosis and more prolonged survival and shared some similar molecular alterations [21,22], clinical and pathological features [21], or even treatment modalities [22,23]. Therefore, LGGs could not be clustered in the group of low-grade gliomas or high-grade glioma simply, and both the research of Zhao et al [17] and the study of Yang et al [20] were not well applicable for LGGs.…”

Section: Discussionmentioning

confidence: 99%

Nomograms individually predict the overall survival and cancer-specific survival of adult patients with hemispheres lower-grade gliomas: A SEER-Based Study

Che

Lyu

et al. 2021

Preprint

View full text Add to dashboard Cite

(1) Background: The 2016 WHO classification of Tumors of the Central Nervous System brought an escalating research interest in lower-grade gliomas (LGGs). This study aims to establish individualized prognostic nomograms to predict the overall survival (OS) and cancer-specific survival (CSS) of patients with LGGs;(2) Methods: We searched the Surveillance, Epidemiology, and End Results (SEER) database for adult patients diagnosed with LGGs from 1998 to 2016. The patient data set selected from SEER was randomly divided into training and validation data sets at a ratio of 7:3. The significant prognostic factors were identified by using multivariate regression models in the training dataset. Then OS and CSS nomograms were developed and internally validated;(3) Results: After the inclusion and exclusion criteria set, a total of 12,630 patients were enrolled in our research. The prognosticators for OS contained age, sex, race, marital status, surgery, radiotherapy, chemotherapy, tumor size/site, laterality, WHO grade, while only chemotherapy among the 11 indicators mentioned above was not related to CSS. The c-indexes of OS and CSS of the validation cohort were 0.749 and 0.761, respectively. The calibration curve plots showed that the predicted probability of 3-, 5-, and 8-years survival rates corresponded well with the actual observed OS and CSS rates;(4) Conclusion: The present study using the SEER database constructed and internally validated prognostic nomograms to predict the OS and CSS of patients with LGGs. The nomograms showed perfect predictive abilities and may be useful clinical tools for decision aids and better supporting patient counselling.

show abstract

“…The incidence of an IDH mutation is very high in patients with WHO grade II-III glioma (more than 80%) and secondary glioblastoma (GBM) (73%), while it is uncommon among patients with primary GBM (3.7%) [2][3][4][5]. Gain-of-function of the IDH gene results in increased intracellular levels of 2-hydroxyglutarate, which leads to alterations of DNA methylation [11]. The final biological effect is cellular dedifferentiation and growth promotion, mainly mediated by gene transcription deregulation.…”

Section: Introductionmentioning

confidence: 99%

“…The final biological effect is cellular dedifferentiation and growth promotion, mainly mediated by gene transcription deregulation. Clinically, IDH-mutated tumors present prolonged survival and an improved response to chemotherapy as compared to IDH-wild type gliomas [11]. Indeed, IDH-wild type gliomas often amplify epidermal growth factor receptor (EGFR), gain of chromosome 7 and loss of chromosome 10 and telomerase reverse transcriptase (TERT) promoter mutations [11,12].…”

Section: Introductionmentioning

confidence: 99%

IDH1 Non-Canonical Mutations and Survival in Patients with Glioma

Franceschi¹,

Biase

Nunno³

et al. 2021

Diagnostics

View full text Add to dashboard Cite

Background: Non-canonical mutations of the isocitrate dehydrogenase (IDH) genes have been described in about 20–25% and 5–12% of patients with WHO grade II and III gliomas, respectively. To date, the prognostic value of these rare mutations is still a topic of debate. Methods: We selected patients with WHO grade II and III gliomas and IDH1 mutations with available tissue samples for next-generation sequencing. The clinical outcomes and baseline behaviors of patients with canonical IDH1 R132H and non-canonical IDH1 mutations were compared. Results: We evaluated 433 patients harboring IDH1 mutations. Three hundred and ninety patients (90.1%) had a canonical IDH1 R132H mutation while 43 patients (9.9%) had a non-canonical IDH1 mutation. Compared to those with the IDH1 canonical mutation, patients with non-canonical mutations were younger (p < 0.001) and less frequently presented the 1p19q codeletion (p = 0.017). Multivariate analysis confirmed that the extension of surgery (p = 0.003), the presence of the 1p19q codeletion (p = 0.001), and the presence of a non-canonical mutation (p = 0.041) were variables correlated with improved overall survival. Conclusion: the presence of non-canonical IDH1 mutations could be associated with improved survival among patients with IDH1 mutated grade II–III glioma.

show abstract

A basic review on systemic treatment options in WHO grade II-III gliomas

Cited by 54 publications

References 58 publications

Health-related quality of life in patients with primary brain tumors during and three months after treatment with proton beam therapy

Health-related quality of life in patients with primary brain tumors during and three months after treatment with proton beam therapy

Nomograms individually predict the overall survival and cancer-specific survival of adult patients with hemispheres lower-grade gliomas: A SEER-Based Study

IDH1 Non-Canonical Mutations and Survival in Patients with Glioma

Contact Info

Product

Resources

About